| 1 |
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne Louise Topalian et al. · New England Journal of Medicine
Open access |
14 Jun 2012 |
12,842 |
| 2 |
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei et al. · New England Journal of Medicine
Open access |
27 Sep 2015 |
9,557 |
| 3 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie Renee Brahmer et al. · New England Journal of Medicine
Open access |
31 May 2015 |
8,632 |
| 4 |
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al. · New England Journal of Medicine
Open access |
16 Oct 2013 |
6,826 |
| 5 |
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva Swarup Neelapu et al. · New England Journal of Medicine
Open access |
10 Dec 2017 |
6,098 |
| 6 |
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al. · The Lancet
Open access |
5 Mar 2016 |
3,762 |
| 7 |
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
Thierry André et al. · New England Journal of Medicine
Open access |
2 Dec 2020 |
3,130 |
| 8 |
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al. · New England Journal of Medicine
Open access |
30 Sep 2012 |
2,838 |
| 9 |
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al. · New England Journal of Medicine
Open access |
24 Feb 2021 |
2,554 |
| 10 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,066 |
| 11 |
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
Eng-Juh Yeoh et al. · Cancer Cell
Open access |
Mar 2002 |
1,928 |
| 12 |
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al. · New England Journal of Medicine
Open access |
Apr 2020 |
1,874 |
| 13 |
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur S Raje et al. · New England Journal of Medicine
Open access |
May 2019 |
1,775 |
| 14 |
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst et al. · New England Journal of Medicine
Open access |
30 Sep 2020 |
1,734 |
| 15 |
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West, Michael McCleod, Maen Hussein et al. · The Lancet Oncology
|
20 May 2019 |
1,711 |
| 16 |
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al. · Cancer Discovery
Open access |
17 May 2018 |
1,671 |
| 17 |
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
M.C. Liu et al. · Annals of Oncology
Open access159 authors |
30 Mar 2020 |
1,567 |
| 18 |
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gϋnter von Minckwitz, Marion Jennifer Procter, Evandro de Azambuja et al. · New England Journal of Medicine
Open access |
5 Jun 2017 |
1,425 |
| 19 |
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
David R. Spigel et al. · Journal of Clinical Oncology
Open access |
2 Feb 2022 |
1,400 |
| 20 |
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi Krishna Murthy et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
1,345 |
| 21 |
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill F. Hallin et al. · Cancer Discovery
Open access |
28 Oct 2019 |
1,328 |
| 22 |
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott Joseph Antonia et al. · The Lancet Oncology
Open access |
5 Jun 2016 |
1,263 |
| 23 |
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman, Jeffery Scott Russell, Omid Hamid et al. · The Lancet Oncology
Open access |
7 Sep 2016 |
1,235 |
| 24 |
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Do‐Youn Oh et al. · NEJM Evidence
|
Jun 2022 |
1,205 |
| 25 |
Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain, Mythili Shastry, Erika Paige Hamilton · Nature Reviews Drug Discovery
ReviewOpen access |
7 Nov 2022 |
1,156 |
| 26 |
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Ranjana H. Advani et al. · New England Journal of Medicine
Open access |
31 Oct 2018 |
1,149 |
| 27 |
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Alice Tsang Shaw, Todd Michael Bauer, Filippo de Marinis et al. · New England Journal of Medicine
Open access |
18 Nov 2020 |
1,111 |
| 28 |
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Pasi Antero Janne et al. · New England Journal of Medicine
Open access |
3 Jun 2022 |
1,051 |
| 29 |
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R.D. Johnston et al. · Journal of Clinical Oncology
Open access |
20 Sep 2020 |
1,037 |
| 30 |
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber et al. · The Lancet
|
21 Jan 2024 |
871 |
| 31 |
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Edward Dela Cruz Drilon et al. · Cancer Discovery
Open access |
9 Feb 2017 |
836 |
| 32 |
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino, Erika Paige Hamilton, Sara M. Tolaney et al. · Journal of Clinical Oncology
|
24 Apr 2020 |
827 |
| 33 |
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett Michael Frampton et al. · Cancer Discovery
|
13 May 2015 |
812 |
| 34 |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al. · The Lancet Oncology
|
6 Nov 2018 |
805 |
| 35 |
Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
Lori J. Wirth et al. · New England Journal of Medicine
Open access |
26 Aug 2020 |
801 |
| 36 |
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodríguez‐Otero et al. · New England Journal of Medicine
Open access |
10 Feb 2023 |
768 |
| 37 |
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al. · Nature Communications
Open access |
30 Aug 2016 |
722 |
| 38 |
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo et al. · Clinical Cancer Research
Open access |
22 May 2017 |
696 |
| 39 |
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Sara A. Hurvitz et al. · The Lancet
Open access |
7 Dec 2022 |
683 |
| 40 |
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Hossein Borghaei et al. · Journal of Clinical Oncology
Open access |
15 Jan 2021 |
683 |
| 41 |
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice Tsang Shaw, Enriqueta Felip, Todd Michael Bauer et al. · The Lancet Oncology
Open access |
23 Oct 2017 |
662 |
| 42 |
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood
Open access |
4 Mar 2014 |
646 |
| 43 |
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Suzanne Louise Topalian, Frank Stephen Hodi, Julie Renee Brahmer et al. · JAMA Oncology
Open access |
25 Jul 2019 |
645 |
| 44 |
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi, Gatien Moriceau, Xiangju Kong et al. · Nature Communications
Open access |
6 Mar 2012 |
642 |
| 45 |
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff Porter Sharman et al. · The Lancet
Open access |
Apr 2020 |
633 |
| 46 |
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Natasha B. Leighl, Ray D. Page, Victoria M. Raymond et al. · Clinical Cancer Research
|
15 Apr 2019 |
612 |
| 47 |
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Adrianus Johannes De Langen et al. · The Lancet
Open access |
7 Feb 2023 |
609 |
| 48 |
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al. · Journal of Clinical Oncology
Open access |
20 Feb 2019 |
605 |
| 49 |
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Ryan Bruce Corcoran et al. · Cancer Discovery
Open access |
8 Feb 2018 |
599 |
| 50 |
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton, Karim S. Fizazi, Alison Stopeck et al. · European Journal of Cancer
|
10 Sep 2012 |
592 |